Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM

Barchart · 10/17 15:30

Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling

Initial Data from Cohort 1 to be Reported in December 2024

Read more at globenewswire.com